JeanChristophe Tellier - UCB SA Insider

UCBJY -- USA Stock  

USD 46.45  0.002  0.0043%

  Chairman
Mr. JeanChristophe Tellier has served as Chairman of the Executive Committee, Chief Executive Officer, Executive Director of UCB S.A. since January 1, 2015. Before that, he was Member of the Executive Committee, Executive Vice President and President of European Operations of the Company from July 1, 2011. He joined the Company from Ipsen where he was President General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen specialty care business in North America, in the areas of endocrinology and neurology. He joined Ipsen in May 2009. He started his career in 1988 in the marketing department of Synthelabo and joined Ciba France as Group Marketing Manager in 1990 and got various marketing sales position until leading the Marketing Sales department. In 1997, following the merger of Ciba and Sandoz to form Novartis, he was appointed Head of the Mass Market Business unit in France until the end of 1999 where he became Chief Operating Officer of Novartis France. From 2003 to mid2006, JC Tellier was Chief Executive Officer of Novartis Pharma Belgium and during his tenure was elected president of Pharma.be, the Pharma trade association. At the end of 2006, he was promoted to Head of the Global Arthritis, Bone and Muscle disease Business Franchise at Novartis Headquarters in Basel, Switzerland. In February 2007, he was appointed Chairman and CEO of Novartis Pharma France and Novartis Group France until mid 2008 when he decided to join MacroGenics Inc., a Marylandbased biotechnology company, as Executive Vice President and Chief Commercial Officer. He is physician specialized in rheumatology and followed diverse executive training both at INSEAD and Harvard.
Age: 58  Chairman Since 2015      
32 2 559 99 99  http://www.ucb.com

Management Efficiency

The company has return on total asset (ROA) of 7.3 % which means that it generated profit of $7.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.56 % meaning that it generated $15.56 on every $100 dollars invested by stockholders.
The company has accumulated 1.94 B in total debt with debt to equity ratio (D/E) of 28.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.2 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 14 records

CHAIRMAN Since

JeanJacques BienaimeBioMarin Pharmaceutical
2015
Jeffrey LeidenVertex Pharmaceuticals Incorpor
2012
Stelios PapadopoulosBiogen
2014
Goran AndoNovo Nordisk AS
2013
John MartinGilead Sciences
2018
Roy VagelosRegeneron Pharmaceuticals
1995
Susan KilsbyShire plc
2014
Joshua BogerVertex Pharmaceuticals Incorpor
2009
Pierre LapalmeBioMarin Pharmaceutical
N/A
Robert HuginCelgene Corporation
2016
Robert BradwayAmgen
2013
David KapplerShire plc
2008
Jeppe ChristiansenNovo Nordisk AS
2013
John ShineCSL Limited
2011

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7500 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,500 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Bollinger Bands

Also Currentnly Active

Purchased a lot of shares of
a day ago
Traded for 156.0
Purchased a lot of shares of
a day ago
Traded for 156.0
Purchased over 300 shares of
a day ago
Traded for 9.81
Also please take a look at World Market Map. Please also try ETF Directory module to find actively-traded exchange traded funds (etf) from around the world.
Search macroaxis.com